O-glycan-dependent immunotherapy for cancer
Ended Project Grant Awarded Last action
- Award ID
- R41CA233111
- Recipient
-
Glytr Therapeutics, Inc. UEI ZKQLT6S8LXY9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,614
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $2,084 | |
| Amendment | $0 | |
| Original award | $298,530 |
Quick answers
Who received award R41CA233111?
R41CA233111 was awarded to Glytr Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2018.
How much is award R41CA233111 worth?
$300,614 has been obligated on R41CA233111.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award